Smith & Nephew plc (ETR:NPW1)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.42B +0.2% |
| Revenue (ttm) | 5.25B +6.1% |
| Net Income | 532.31M +51.7% |
| EPS | 0.61 +52.3% |
| Shares Out | n/a |
| PE Ratio | 21.46 |
| Forward PE | 13.82 |
| Dividend | 0.33 (2.50%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | 20 |
| Open | 13.40 |
| Previous Close | 13.30 |
| Day's Range | 13.40 - 13.40 |
| 52-Week Range | 12.50 - 16.57 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew price target lowered to 1,550 GBp from 1,600 GBp at Citi
Citi lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,600 GBp and keeps a Buy rating on the shares.
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single...
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of ...
Smith & Nephew PLC (SNN) Stock Down 4.8% -- Now Undervalued? GF Score: 84/100
Smith & Nephew PLC (SNN) Stock Down 4.8% -- Now Undervalued? GF Score: 84/100
Smith & Nephew price target lowered to 1,333 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Smith & Nephew to 1,333 GBp from 1,507 GBp and keeps an Overweight rating on the shares.
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.2% Rally? GF Value Says Undervalued
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.2% Rally? GF Value Says Undervalued
Smith & Nephew Transcript: Investor update
The event showcased a robust innovation pipeline across wound care, sports medicine, orthopedics, and enabling technologies, with a focus on ASC efficiency and data-driven solutions. Key platforms like CORI, Landmark, AETOS, and TESSA are positioned to drive growth, supported by strong clinical evidence and surgeon advocacy.
Smith & Nephew Slides: Investor update
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, ...
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy with a price target of 1,230 GBp, down from 1,462 GBp. The firm sees limited near-term catalysts for a re-rating…
Smith & Nephew downgraded to Hold from Buy at Kepler Cheuvreux
Kepler Cheuvreux downgraded Smith & Nephew to Hold from Buy.
Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform d...
Smith & Nephew added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added Smith & Nephew to the firm’s European Conviction List as part of its monthly update. The company’s guidance reset brings an opportunity to revisit a name…
Smith & Nephew Slides: Investor presentation
Smith & Nephew has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Smith & Nephew price target lowered to 1,550 GBp at Goldman Sachs
Goldman Sachs analyst Richard Felton lowered the firm’s price target on Smith & Nephew to 1,550 GBp from 1,700 GBp and keeps a Buy rating on the shares. The firm…
Smith & Nephew price target lowered to $30 from $32 at Canaccord
Canaccord lowered the firm’s price target on Smith & Nephew to $30 from $32 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein
Bernstein lowered the firm’s price target on Smith & Nephew to $31.85 from $36.20 and keeps a Market Perform rating on the shares after the company provided a Q1 trading…
Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,350 GBp from 1,300 GBp and keeps an Equal Weight rating on the shares. Th firm updated the company’s…
Smith & Nephew Earnings Call Transcript: Q1 2026
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
Smith & Nephew Slides: Q1 2026
Smith & Nephew has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Smith & Nephew Earnings release: Q1 2026
Smith & Nephew released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annu...
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...
Smith & Nephew price target lowered to $32 from $35 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model…
Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
Smith+Nephew announces further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its Cartiheal Agili-C Cartilage Repair Implant recently published in th...